Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 174 de 371.

Grafa
Industrials

CSW Industrials posts record fiscal 2026 sales on acquisition surge

CSW Industrials (NYSE:CSW) reported record financial results for both the fourth quarter and the full fiscal year of 2026, navigating higher interest expenses and non-cash charges through a combination of aggressive acquisition integration and a return to organic expansion in its core segment.

Leia mais: CSW Industrials posts record fiscal 2026 sales on acquisition surge
Grafa

Freightos gross booking value surges 24% as higher rates offset volume headwinds

Freightos (NASDAQ:CRGO) reported mixed financial and operational metrics for the first quarter of 2026, as geopolitical tensions and airspace restrictions across the Middle East slowed core transaction growth while simultaneously driving up global shipping rates to support the logistics platform's overall transaction value.

Leia mais: Freightos gross booking value surges 24% as higher rates offset volume headwinds
Grafa

Genprex pinpoints key biomarkers to predict Reqorsa gene therapy success at ASCO

Genprex (NASDAQ:GNPX) announced the official abstract publication of positive clinical biomarker data for its lead oncology candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Leia mais: Genprex pinpoints key biomarkers to predict Reqorsa gene therapy success at ASCO
Grafa

Biohaven seizure drug extends remission in broad clinical data update

Biohaven (NYSE:BHVN) released new clinical and safety data for opakalim, its selective Kv7.2/7.3 potassium channel activator, showing meaningful reductions in seizure frequency and a highly differentiated central nervous system safety profile across generalized and focal forms of epilepsy.

Leia mais: Biohaven seizure drug extends remission in broad clinical data update
Grafa

NervGen gene therapy slashes functional deficits in spinal cord injury trial

NervGen Pharma (NYSE:NGEN) reported positive results from an independent, blinded biomechanical gait analysis of its Phase 1b/2a CONNECT SCI study, demonstrating that its lead candidate, NVG-291, achieved statistically significant improvements in walking quality among chronic spinal cord injury patients.

Leia mais: NervGen gene therapy slashes functional deficits in spinal cord injury trial
Grafa
Oil and Gas

Northern Oil and Gas enters Canada with CA$350 million Duvernay deal

Northern Oil and Gas (NYSE:NOG) agreed to acquire an undivided 25% non-operated interest in light oil assets within Alberta’s Duvernay Shale for an initial unadjusted purchase price of CA$350 million (approximately US$259 million), marking the company’s first expansion outside of the United States.

Leia mais: Northern Oil and Gas enters Canada with CA$350 million Duvernay deal
Grafa

Kura Oncology combination shrinks solid tumors in 77% of trial patients

Kura Oncology (NASDAQ:KURA) reported preliminary Phase 1a data from its FIT-001 clinical trial, showing that a combination of its next-generation farnesyl transferase inhibitor darlifarnib and adagrasib induced tumor shrinkage in 77% of evaluable patients with advanced solid tumors.

Leia mais: Kura Oncology combination shrinks solid tumors in 77% of trial patients